


Biomimetic Phosphate-Catalyzed Pictet–Spengler Reaction for the Synthesis of 1,1'-Disubstituted and Spiro-Tetrahydroisoquinoline Alkaloids

Jianxiong Zhao,[†] Daniel Méndez-Sánchez,[†] John M. Ward,[‡] and Helen C. Hailes^{*,†}[†]Department of Chemistry, University College London, Christopher Ingold Building, 20 Gordon Street, London WC1H 0AJ, U.K.[‡]Department of Biochemical Engineering, University College London, London WC1E 6BT, U.K.**S** Supporting Information

ABSTRACT: Tetrahydroisoquinoline (THIQ) alkaloids are an important group of compounds that exhibit a range of bioactivities. Here, a phosphate buffer-catalyzed Pictet–Spengler reaction (PSR) using unreactive ketone substrates is described. A variety of 1,1'-disubstituted and spiro-tetrahydroisoquinoline alkaloids were readily prepared in one-step and high yields, highlighting the general applicability of this approach. This study features the role of phosphate in the aqueous-based PSR and provides an atom-efficient, sustainable route to new THIQs.

**■ INTRODUCTION**

Tetrahydroisoquinolines (THIQs) are an important group of pharmacologically active compounds exhibiting for example, anticancer, antimalarial, analgesic, antithrombotic, and central nervous system-related activities. A subgroup of THIQs, the benzylisoquinoline alkaloids (BIAs) are a key family of natural products found in higher plants and mammals.¹ The BIAs in particular have attracted the attention of many researchers in recent years, giving rise to a range of patents and publications.^{2–8} Amongst the THIQs, 1,1'-spiro compounds have proven to be synthetically challenging to synthesize, and they include the antiplasmodial compound **1**, natural product ochotensines **2** and **3**, and trabectedin **4** (Figure 1).^{9–11}




Figure 1. Selected 1,1'-spiro tetrahydroisoquinoline alkaloids.

Different strategies have been used to access THIQs, including natural product extraction from plant sources, affording the desired alkaloids in low yields. In recent years, efforts have also been focused on the expression of biocatalysts for use in the stereoselective synthesis of these alkaloids. For example, in plants norcochloraurine synthases (NCSs) catalyze the first committed step in the BIA biosynthetic pathway, between

dopamine **5** and 4-hydroxyphenyl acetaldehyde (4-HPAA) and they have been used in the synthesis.^{12–15}

The Pictet–Spenglerase NCS has proven to be particularly tolerant towards a range of aldehydes and more recently has been reported to accept ketones.^{16–20} While the use of NCS to generate 1,1'-substituted THIQs is a particularly powerful strategy in stereoselective synthesis, a complementary method to access achiral compounds, or an approach that does not necessitate the production of biocatalysts would also be highly valuable.


Many methods have been reported for synthesizing THIQs including the Pictet–Spengler or Bischler–Napieralski reactions,^{21,22} but typically for these reactions, particularly when using ketones, high temperatures, strong acids, or superacids are required.^{23,24} An example includes the reaction of 1-(3-hydroxyphenyl)-2-aminoethanol with cyclohexanone to give a spirooxazolidine which when fused at 150 °C produces 1,1'-spiro-hexanotetrahydroisoquinoline.^{25,26} Such reaction conditions are however incompatible with less stable phenethylamines such as catechols. To overcome some of these problems, Lewis acid catalysts such as *o*-benzenedisulfonamide,²⁷ titanium(IV) isopropoxide,²⁸ or calcium bis-1,1,1,3,3,3-hexafluoroisopropoxide²⁹ have been used (Scheme 1a,b), but there are inherent limitations associated with the preparation of such catalysts including high costs or the requirement of a drybox.²⁹ In addition, the key phenolic groups must be protected or side products can be formed. Phosphate salts are a useful alternative due to the lower costs and milder reaction conditions that can be used.³⁰ Indeed, we have previously reported the use of aqueous phosphate in a Pictet–Spengler reaction (PSR) for the synthesis of THIQs

Received: February 22, 2019


Published: May 16, 2019

Scheme 1. (a,b) Reported Lewis Acid-Catalyzed PSRs with Ketones; (c) Previous Aqueous Phosphate-Mediated PSRs with Aldehydes; (d) PSRs with Ketones Reported in This Work

Previous work



This work



(Scheme 1c).³⁰ The reaction was extended to a range of aromatic, aliphatic, and heterocyclic aldehydes, but not with ketone substrates which are more sterically challenging and less reactive.

Here, we describe the discovery that aqueous phosphate reaction conditions can also be used to synthesize THIQs using ketones. The reaction conditions were optimized and applied to variously decorated phenethylamines and a wide range of cyclic and acyclic ketones in high yield (Scheme 1d). Some of the THIQs synthesized have also been reported to possess interesting bioactivities, including antiparasitic properties.¹⁰


RESULTS AND DISCUSSION

Aqueous phosphate media have previously been used to produce norcoclaurine from dopamine **5** and 4-HPAA via a PSR, and the reaction was extended to a range of aldehyde substrates.³⁰ Despite this facile approach of using catechols to generate THIQs, an extension to ketone substrates has received little attention, other than the work by Tono et al. who noted that acetone might couple with dopamine in phosphate buffer (0.1 M, pH 7.2), although the product was not characterized.³¹ In addition, the extraction of dopamine from the Chinese yam with acetone was believed to form a THIQ and the characterization of plant acetone extracts from *Aristolochia arcuata* highlighted that a THIQ was formed from dopamine and acetone.^{32,33} The main challenge with the PSR reaction using ketones is the relatively low reactivity, which when combined with the sensitivity of catechols can lead to the formation of many side products. However, inspired by the interesting NCS mediated PSR reaction with ketones it was decided to investigate whether an aqueous biomimetic phosphate-based approach could also be developed.¹⁹

First, to avoid side reactions because of the oxidation of catechols, such as dopamine **5**, the antioxidant sodium ascorbate was added to the reactions.²⁰ Cyclohexanone **6** was then used in a reaction with potassium phosphate (KPi, 1 M) with acetonitrile as the cosolvent at pH 6 and 70 °C and surprisingly, the PSR product **7** was formed in 11% yield

(Table 1, entry 1). Because different phosphate anions predominate at different pHs, at pH 6 the major ion is

Table 1. Initial Optimization of the Model Reaction Using **5** and **6** To Give **7**^a




entry	6 (equiv)	KPi pH	co-solvent	yield 7 (%) ^b
1	1.3	6	MeCN	11
2	1.3	4	MeCN	0
3	1.3	12	MeCN	0
4	1.3	9	MeCN	16
5	1.3	9	DMSO	14
6	1.3	9	EtOH	21
7	1.3	9	MeOH	43
8	1.3	9	none	36
9	2.0	9	MeOH	46
10	5.0	9	MeOH	81
11	10.0	9	MeOH	97

^aReactions conditions: dopamine **5** (15–25 mM), cyclohexanone **6** (20–150 mM), and sodium ascorbate (1.0 equiv relative to dopamine) on a 1 mL scale in 1 M KPi, pH 9 and 50% co-solvent (v/v) at 70 °C. ^bYields were determined by analytical HPLC.

H_2PO_4^- , alternative pHs were explored. Unsurprisingly, no product **7** was observed at pH 4, due to dopamine protonation, and pH 12 due to the oxidation of dopamine which is prevalent at high basic pHs. However, at pH 9 the yield increased to 16% (Table 1, entry 4; see Supporting Information Figure S1 for further data on the effect of pH). A pH of 9 was then used as a suitable starting point for further reaction optimization. Density functional theory (DFT) and MP2 methods have been used in a theoretical study exploring the phosphate-mediated PSR with 3-hydroxyphenethylamine and formaldehyde, which suggested that the lowest energy pathway required both HPO_4^{2-} and H_2PO_4^- for optimal catalysis in the phosphate biomimetic reaction.³⁴ At pH 9, HPO_4^{2-} is the predominant anion present (with some H_2PO_4^-) and can facilitate both the deprotonation of the *meta*-phenolic OH and abstraction of 8a-H in the isoquinolone intermediate.

Typically, a cosolvent was required when developing the phosphate PSR reaction with aldehydes where aldehyde solubility was poor so other cosolvents were investigated, also with a view to enhancing yields. The polar aprotic solvents dimethyl sulfoxide (DMSO), dimethylformamide (DMF), and 1,4-dioxane together with the polar protic solvents methanol, ethanol, and isopropanol were investigated (Table 1 and Supporting Information Figure S2). While DMSO had little effect on the yield, it decreased when using DMF, 1,4-dioxane, and isopropanol. However, the reaction yields were higher with ethanol (Table 1, entry 6) and in particular methanol which was superior to other cosolvents (Table 1, entry 7), giving a 43% yield of **7**. Further studies established that lower proportions of methanol (10–40% v/v, data not shown) generated similar yields of **7**, and in the absence of a cosolvent, 36% of **7** was formed. This presumably reflects the fact that in the case of **6** there were no solubility issues in water.

To improve the synthetic utility, the reaction temperature was increased to 80 and 90 °C with little effect. Upon

Scheme 2. Application of the Phosphate-Catalyzed PSR to Synthesize 1,1'-Disubstituted and Spiro-THIQ Alkaloids^a

^aTypical reaction conditions: dopamine **5** (15–25 mM), ketone (20–150 mM), and sodium ascorbate (1.0 equiv relative to dopamine or the corresponding phenethylamine) were reacted together on a 1 mL scale in 0.3 M KPi, pH 9 and methanol (50% v/v of methanol and ketone combined) at 70 °C. Small scale reactions were performed in duplicate or triplicate. Yields were determined by ¹H NMR spectroscopy with an internal standard (maleic acid), and also by HPLC analysis (see Supporting Information, Table S5 for HPLC retention times) for several examples to confirm the data. ^b10 equiv of the corresponding ketones were used. ^c50 equiv of the corresponding ketones were used. All products were isolated (yields are in brackets) either from these small scale reactions or larger reactions and purified, using the acid–base extraction method or preparative HPLC, for characterization purposes.

increasing the number of equivalents of **6** from 1.3 to 2, 5, and 10 equiv, in the latter case, **7** was formed in quantitative yield (Table 1, entry 11), so this was used in further experiments. The effect of using lower KPi concentrations was also investigated using **5** and **6** (Supporting Information, Table S1). Concentrations of 0.1–1 M KPi gave **7** in 97% yield, and below 0.1 M the yield of **7** decreased. To ensure sufficient KPi was present, a 0.3–0.5 M KPi concentration was therefore selected. The effect of the dopamine **5** concentration in the reaction was also explored (Supporting Information, Table S2). The yield remained constant with concentrations of up to 0.3 M, decreasing to 48% with 1 M of **5** when solubility issues were encountered.

With optimized reaction conditions in hand, we were curious to understand the requirements for phosphate in the reaction. Alternative buffers or bases were used at pH 9 including KOH, KHCO₃–K₂CO₃ (0.5 M), Na₃BO₃ (0.5 M), and Na₂SO₃ (saturated) together with water alone (Supporting Information, Table S3). When water, water adjusted to pH 9 using KOH, or Na₃BO₃ solution was used, **7** was formed in trace amounts in reactions with 10 mM of **5** (Supporting Information, Table S3). These increased to 8–15% yields in reactions using 50 mM of **5** (Supporting Information, Table S4). Interestingly, with KHCO₃–K₂CO₃ and Na₂SO₃ at pH 9 yields of 24 and 43% with 10 mM **5** were noted, increasing to 63 and 89% with 50 mM **5**, respectively. At both dopamine concentrations the highest yields were still observed with KPi. The role of phosphate in previous experiments for aldehyde PSRs has been probed using DFT and MP2 methods in a

theoretical study.³⁴ The proposed reaction scheme for 3-hydroxyphenethylamine and formaldehyde involved both HPO₄²⁻ and H₂PO₄⁻ having a role in the formation of a complex with the iminium intermediate, and after cyclization, H₂PO₄⁻ assisting in the deprotonation at 8a-H of isoquinoline, while also being complexed to the amine proton. The lower yields observed with KHCO₃–K₂CO₃ of 24% (10 mM **5**) and 63% (50 mM **5**) may reflect that the trigonal planar geometry of carbonate is unlikely to be able to perform a similar role of deprotonation and amine proton complexation as readily as H₂PO₄⁻ (or potentially HPO₄²⁻) in the re-aromatization step, compared to tetrahedral phosphate. The relatively high yields with Na₂SO₃ were interesting and may be due to its trigonal pyramidal structure, enabling the re-aromatization step in a similar fashion to KPi, combined with the reducing environment it provides. Overall, KPi gave rise to the highest yields and so was used in further experiments. It was also noted that in the reaction between **5** and **6** for the KPi concentrations used, no ortho-regioisomer was detected presumably because of steric reasons.³⁵

With suitable reaction conditions established, the general applicability of the reaction was explored for the synthesis of a range of 1,1'-disubstituted and spiro-THIQ alkaloids (Scheme 2). Reactions were monitored by ¹H NMR spectroscopy because of the reported challenges with product isolation.²⁹ In addition, to confirm the NMR data, for several reactions, the yields were confirmed by high-performance liquid chromatography (HPLC) analysis. The phosphate mediated PSR could tolerate a range of methyl ketones, giving **8**–**12** in 54–95%

yield when using aliphatic ketones. The reaction yields were greater for **8** and **9**, reflecting the influence of the increasing alkyl chain length and associated steric effects in the intermediates and subsequent cyclizations to give products **10–12**. For the aromatic ketones acetophenone or phenyl acetone giving **13** and **14**, respectively, again poor reactivities were observed, reflecting unfavorable steric interactions in the cyclization step to generate the THIQs. The introduction of a trifluoromethyl group, however, was readily achieved giving **15** in 93% yield.

The introduction of a third cyclic or heterocyclic ring could more widely be introduced into the THIQ scaffold, following the model reaction to give **7**. Using 3- or 4-methyl cyclohexanone readily gave **16** and **17** in 70 and 80% yields, respectively. Similarly, with 4-isopropyl cyclohexanone, **18** was generated in 75% yield and using tetrahydro-4*H*-pyran-4-one **19** was formed in 83% yield. When using cyclobutanone and cyclopentanone THIAAs **20** and **21** were formed in 97 and 95% yields, comparable yields to when using **6**, highlighting that other ring sizes can be readily used in the phosphate-catalyzed Pictet–Spengler condensation. Furthermore, the use of 1- or 2-indanone afforded the tetracyclic ochotensine⁹ derivatives **22** and **23** in 70 and 21% yields, respectively.

In addition to using alternative ketone substrates, selected substituted phenethylamines were investigated (Scheme 2). 2-(3-Hydroxyphenyl)ethylamine²⁰ was used with **6** to synthesize **24**, a compound previously synthesized in 2 steps in 10% yield, and reported to possess antimalarial properties.¹⁰ A yield of 74% was achieved and the product was isolated by preparative HPLC in 53% yield. The fluorinated analogue 4-fluoro-3-hydroxy phenethylamine was also used to give **25** in 55% yield. A regioisomer of dopamine, 5-(2-aminoethyl)benzene-1,3-diol,³⁶ which will provide more unfavorable steric interactions was investigated and gave **26** in a reasonable 57% yield.


To highlight the utility of this methodology, the synthesis of **7** and **20** as selected compounds were then performed on a 1 g scale. The reaction yields by ¹H NMR spectroscopy were 97%, and at this larger scale it was possible to isolate the materials using an acid–base extraction method to give **7** in 40% yield and **20** in 51% yield.

The use of a ketone possessing ester functionality for subsequent ring cyclization was also investigated to establish a reaction cascade to form an additional ring, as this strategy with an aldehyde had been successfully used to generate the antibacterial trolline.²⁰ Using the ketone KPi reaction conditions established, **5** was reacted with commercially available methyl levulinate **27** to form a linear intermediate **28** with a C-1 quaternary carbon. Spontaneous cyclization by nucleophilic attack of the amine at the ester carbonyl, following the favored 5-*exo*-trig mode, afforded lactam **29** in 50% yield (by ¹H NMR spectroscopy) (Scheme 3).

CONCLUSIONS

In summary, a biomimetic approach for the synthesis of 1,1'-disubstituted and spiro-THIQs has been established using a PSR with unactivated ketones. The reaction is readily performed in methanol/phosphate buffer at pH 9 and 70 °C; these are significantly milder reaction conditions than those previously reported. The reaction successfully used methyl ketones, cyclic ketones, and aromatic ketones with phenethylamines bearing a *meta*-hydroxyl group. Overall, this study provides a low cost and sustainable way of making C-1,1'

Scheme 3. Application of the KPi-Catalyzed PSR with **27** in a Cascade Reaction



disubstituted THIQ alkaloids using phosphate buffer, to afford a range of products in high yields using a facile procedure.

EXPERIMENTAL SECTION

General Information. All chemicals were obtained from commercial suppliers and used as received. Small-scale reactions were heated using a BIOER Mixing block MB-102, and the scale-up reactions were heated using a Heidolph MR Hei-Tec type heating mantle. Thin layer chromatography was carried out using Merck TLC silica gel 60 F₂₅₄ plates, and the products were visualized using combinations of UV light (254 nm), potassium permanganate, and phosphomolybdic acid staining solutions. Column chromatography was carried out using silica gel (particle size 40–60 μm). Infrared (IR) spectra were recorded using a PerkinElmer Spectrum 100 FT-IR spectrometer or a Bruker ALPHA PLATINUM-ATR, operating in the ATR mode. ¹H NMR spectra were recorded on Bruker AVANCE 400, 500, 600, and 700 MHz spectrometers at 25 °C, using the residual protic solvent stated as the internal standard. Chemical shifts are quoted in ppm to the nearest 0.01 ppm using the following abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), qn (quintet), sext (sextet), dd (doublet of doublets), dt (doublet of triplets), and m (multiplet) defined as all multiplex signals, where the overlap or complex coupling of signals make definitive descriptions of peaks difficult. The coupling constants are defined as *J* and measured in Hz. ¹³C{¹H} NMR spectra were recorded at 100, 125, 150, or 175 MHz on Bruker AVANCE 400, 500, 600, and 700 MHz spectrometers at 25 °C using the stated solvent as the standard. Chemical shifts are reported to the nearest 0.1 ppm. Melting points were measured with a Gallenkamp apparatus, and were uncorrected.

Mass spectra were obtained using a Waters Acquity UPLC SQD (using a linear gradient of 5–95% of acetonitrile over 5 min, with a C8 column, and flow rate of 0.6 mL/min) and the Waters LCT Premier XE ESI Q-TOF mass spectrometer in the Department of Chemistry, UCL.

Determination of Yields Using ¹H NMR Spectroscopy. The reactions were set up in duplicate (1 mL scale) in Eppendorf tubes which were shaken at 70 °C for 20 h. The reaction mixture was transferred to a round-bottomed flask and evaporated to remove methanol. Water was then removed using a freeze-drier to obtain a solid, which was dissolved in a solution of maleic acid (CD₃OD/D₂O = 1:3, 1 mL) and characterized by ¹H NMR spectroscopy. The concentration of the maleic acid was half of the starting material dopamine. The peak integration of maleic acid proton ($\delta = 5.89$ ppm) was calibrated as 1.00, and the integration ($\times 100\%$) of one of the product aromatic protons was used to determine the NMR yield.

HPLC Methods. Analytical HPLC Methods. HPLC analysis was carried out on an Agilent 1260 Infinity HPLC with a mobile phase (A: water with 0.1% TFA; B: acetonitrile) in a gradient of A/B = 90%/10% at 0–1 min, A/B = 90%/10% to A/B = 30%/70% at 1–6 min, 100% B at 6–6.5 min, and A/B = 90%/10% at 6.5–10 min. Each injection volume was 10 μL. The column was an ACE 5 C₁₈ reverse phase column (150 mm \times 4.6 mm). The flow rate was 1 mL/min and

detection wavelength was 280 nm. The retention time of each compound is given in the Supporting Information, Table S5.

Preparative HPLC Methods. Preparative HPLC was carried out on a Dionex 580 HPLC system, including a P580 Pump, ASI-100 Automated Sample Injector, and PDA-100 Photodiode Array Detector. A C₁₈ reverse phase column, Agilent ZORBAX 300SB-C18 (250 mm × 9.4 mm, 5 μm) was used for purifications. The detection wavelength was 280 nm and the flow rate was 2 mL/min. Chromeleon Client Program software was used to monitor the HPLC traces.

Method I: mobile phase (A: water with 0.1% TFA; B: acetonitrile with 0.1% TFA) in a gradient of A/B = 95%/5% at 0–6 min, A/B = 95%/5% to A/B = 55%/45% at 6–10 min, A/B = 55%/45% at 10–15 min, A/B = 55%/45% to A/B = 10%/90% at 15–16 min, A/B = 10%/90% at 16–18 min, A/B = 10%/90% to A/B = 95%/5% at 18–20 min, A/B = 95%/5% at 20–25 min.

Method II: mobile phase (A: water with 0.1% TFA; B: acetonitrile with 0.1% TFA) in a gradient of A/B = 95%/5% at 0–10 min, A/B = 95%/5% to A/B = 5%/95% at 10–12 min, A/B = 5%/95% at 12–13 min, A/B = 5%/95% to A/B = 95%/5% at 13–14 min, A/B = 95%/5% at 14–30 min.

Method III: mobile phase (A: water with 0.1% TFA; B: acetonitrile with 0.1% TFA) in a gradient of A/B = 85%/15% at 0–30 min.

3',4'-Dihydro-2H-spiro[cyclohexane-1,1'-isoquinoline]-6',7'-diol Hydrochloride (7·HCl). To a solution of dopamine hydrochloride (19 mg, 0.10 mmol) and sodium ascorbate (20 mg, 0.10 mmol) in KPi buffer (0.3 M, pH 9, 0.5 mL) and methanol (0.5 mL), cyclohexanone (104 μL, 1.0 mmol) was added. The reaction mixture was shaken at 70 °C for 18 h and monitored by analytical HPLC. The reaction mixture was diluted to ~7 mL with water and directly purified using the preparative HPLC method I. Fractions were combined, exchanged with HCl (1 M), and evaporated to obtain 7·HCl (19 mg, 70%) as a solid. The NMR yield of the reaction (97%) was determined following the general procedure described. The reaction was scaled-up using 5·HCl (1.00 g, 5.27 mmol) sodium ascorbate (1 equiv with respect to dopamine) in KPi buffer (0.3 M, pH 9, 52.7 mL) and methanol (52.7 mL), and 6 was added (5.48 mL, 52.7 mmol). The reaction mixture was shaken at 70 °C for 20 h, and then the pH was adjusted to 3 by the addition of HCl (2 M). The solvent was removed in vacuo, and the residue suspended in acetonitrile at 0 °C. Finally, the mixture was filtered and the solvent removed in vacuo to give 7·HCl (0.491 g, 40%). ¹H NMR (600 MHz; CD₃OD): δ 6.76 (s, 1H), 6.57 (s, 1H), 3.41 (t, J = 6.4 Hz, 2H), 2.96 (t, J = 6.4 Hz, 2H), 2.10–1.97 (m, 4H), 1.88–1.77 (m, 3H), 1.70–1.60 (m, 2H), 1.52–1.42 (m, 1H); ¹³C{¹H} NMR (151 MHz; CD₃OD): δ 146.4, 146.0, 129.9, 123.1, 116.1, 113.3, 61.0, 38.6, 36.8, 26.2, 25.3, 21.7; m/z [ES⁺] 234 ([MH]⁺, 100%).

1,1-Dimethyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol Hydrochloride (8·HCl). Dopamine hydrochloride (9.5 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in KPi buffer (0.3 M, pH 9, 963 μL) in a capped Eppendorf tube. Acetone (37 μL, 0.50 mmol) was then added and the reaction mixture was shaken under argon at 70 °C. After 18 h, the acetone was removed in vacuo. The remaining solution was freeze-dried and the NMR yield (95%) was determined following the general procedure described. The reaction was also performed in duplicate to confirm the NMR yield and these two reaction products were combined and purified using the preparative HPLC method I. Fractions were combined, exchanged with HCl (1 M) and evaporated at 55 °C to obtain 8·HCl as a white solid (7.4 mg, 32%). ¹H NMR (400 MHz; CD₃OD): δ 6.70 (s, 1H), 6.57 (s, 1H), 3.46 (t, J = 6.4 Hz, 2H, 3-H₂), 2.96 (t, J = 6.4 Hz, 2H, 4-H₂), 1.67 (s, 6H, 2 × CH₃); ¹³C{¹H} NMR (100 MHz; CD₃OD): δ 146.5, 146.2, 129.6, 122.3, 116.1, 112.7, 58.1, 38.8, 28.5, 26.0; m/z [ES⁺] 194 ([MH]⁺, 100%).

1-Ethyl-1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol Hydrochloride (9·HCl). To a solution of dopamine hydrochloride (19 mg, 0.10 mmol) and sodium ascorbate (20 mg, 0.10 mmol) in KPi buffer (0.3 M, pH 9, 1 mL) and methanol (0.55 mL), butanone (0.45 mL, 5.0 mmol) was added. The reaction mixture was shaken at 70 °C for 18 h and monitored by analytical HPLC. The reaction

mixture was diluted to 25 mL with water, washed with ethyl acetate (3 × 20 mL), and evaporated in vacuo to remove residual ethyl acetate, and then directly purified using preparative HPLC method II. Fractions were combined, exchanged with HCl (1 M), and evaporated to give 9·HCl (8.0 mg, 33%) as a white solid. The NMR yield of the reaction (92%) was determined following the general procedure described. mp 129–133 °C (H₂O); ν_{max} (film) 2970, 2792, 1591, 1523 cm⁻¹; ¹H NMR (600 MHz; CD₃OD): δ 6.64 (s, 1H), 6.58 (s, 1H), 3.50–3.36 (m, 2H), 3.03–2.84 (m, 2H), 2.02 (q, J = 7.2 Hz, 2H), 1.63 (s, 3H), 0.98 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (151 MHz; CD₃OD): δ 146.5, 146.1, 128.7, 122.9, 116.2, 113.0, 61.2, 39.0, 34.5, 26.0, 25.9, 8.1; m/z [ES⁺] 208 ([MH]⁺, 100%); m/z [HRMS ES⁺] calcd for C₁₂H₁₈NO₂, 208.1332 [MH]⁺; found, 208.1332.

1-Methyl-1-propyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol Hydrochloride (10·HCl). Dopamine hydrochloride (9.5 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in KPi buffer (0.3 M, pH 9, 500 μL) and methanol (235 μL) in a capped Eppendorf tube. 2-Pentanone (265 μL, 2.50 mmol) was then added and the reaction mixture was shaken under argon at 70 °C. After 20 h the methanol was removed in vacuo and the NMR yield (78%) was determined following the general procedure described. Two further duplicate reactions were performed, and the two reaction products were combined and purified using the preparative HPLC method I. Fractions were combined, exchanged with HCl (1 M), and evaporated at 55 °C to give 10·HCl (11 mg, 43%) as a white solid. mp 237–239 °C (H₂O); ν_{max} (film) 3341, 3127, 2958, 1593, 1530 cm⁻¹; ¹H NMR (600 MHz; CD₃OD): δ 6.65 (s, 1H), 6.58 (s, 1H), 3.49–3.37 (m, 2H), 3.03–2.83 (m, 2H), 1.98–1.90 (m, 2H), 1.64 (s, 3H), 1.49–1.41 (m, 1H), 1.33–1.25 (m, 1H), 0.98 (t, J = 7.2 Hz); ¹³C{¹H} NMR (151 MHz; CD₃OD): δ 146.5, 146.1, 128.9, 122.8, 116.2, 113.0, 60.9, 44.1, 39.0, 26.4, 26.0, 17.8, 14.4; m/z [ES⁺] 222 ([MH]⁺, 100%); m/z [HRMS ES⁺] calcd for C₁₃H₂₀NO₂, 222.1489 [MH]⁺; found, 222.1489.

1-Butyl-1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol Hydrochloride (11·HCl). Dopamine hydrochloride (9.5 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in KPi buffer (0.3 M, pH 9, 500 μL) and methanol (191.6 μL) in a capped Eppendorf tube. 2-Hexanone (308.4 μL, 2.50 mmol) was then added and the reaction mixture was shaken under argon at 70 °C. After 20 h the NMR yield (54%) was determined following the general procedure described. Two further duplicate reactions were performed, and these two reaction products were combined and purified using the preparative HPLC method III. Fractions were combined, exchanged with HCl (1 M), and freeze dried to give 11·HCl (4.6 mg, 34%) as a white solid. mp > 250 °C (H₂O); ν_{max} (film) 3255, 2957, 1599, 1392 cm⁻¹; ¹H NMR (600 MHz; CD₃OD): δ 6.65 (s, 1H), 6.58 (s, 1H), 3.49–3.38 (m, 2H), 3.04–2.93 (m, 1H), 2.89 (dt, J = 17.0, 5.4 Hz, 1H), 2.00–1.93 (m, 2H), 1.63 (s, 3H), 1.45–1.32 (m, 3H), 1.29–1.19 (m, 1H), 0.94 (t, J = 7.2 Hz); ¹³C{¹H} NMR (151 MHz; CD₃OD): δ 146.5, 146.1, 128.9, 122.8, 116.2, 113.0, 60.9, 41.7, 39.0, 26.5, 26.4, 25.9, 23.9, 14.2; m/z [ES⁺] 236 ([MH]⁺, 100%); m/z [HRMS ES⁺] calcd for C₁₄H₂₂NO₂, 236.1648 [MH]⁺; found, 236.1645.

1-(But-3-en-1-yl)-1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol Hydrochloride (12·HCl). Dopamine hydrochloride (9.5 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in KPi buffer (0.3 M, pH 9, 500 μL) and methanol (210.4 μL) in a capped Eppendorf tube. 5-Hexen-2-one (289.6 μL, 2.50 mmol) was then added and the reaction mixture was shaken under argon at 70 °C. After 20 h the NMR yield (60%) was determined following the general procedure described. Two further duplicate reactions were performed, and the two reaction products were combined and purified using the preparative HPLC method III. Fractions were combined, exchanged with HCl (1 M), and freeze dried to give 12·HCl (5.4 mg, 41%) as a white solid. mp > 250 °C (H₂O); ν_{max} (film) 3196, 2957, 1672, 1616, 1369 cm⁻¹; ¹H NMR (600 MHz; CD₃OD): δ 6.67 (s, 1H), 6.59 (s, 1H), 5.82 (dt, J = 16.9, 10.3 Hz, 1H), 5.09 (dd, J = 16.9, 1.5 Hz, 1H), 5.01 (br d, J = 10.3 Hz, 1H), 3.48–3.42 (m, 2H), 2.99–2.96 (m, 1H), 2.95–2.89 (m, 1H), 2.24–2.15 (m, 1H), 2.08–2.01 (m, 3H), 1.67 (s, 3H); ¹³C{¹H} NMR (151 MHz;

CD₃OD): δ 146.6, 146.2, 137.9, 128.5, 122.9, 116.24, 116.18, 113.0, 60.8, 41.1, 39.1, 28.8, 26.4, 25.9; m/z [ES⁺] 234 ([MH]⁺, 100%); m/z [HRMS ES⁺] calcd for C₁₄H₂₀NO₂, 234.1489 [MH]⁺; found, 234.1490.

1-Methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol Hydrochloride (13-HCl). To a solution of dopamine hydrochloride (95 mg, 0.50 mmol) and sodium ascorbate (100 mg, 0.50 mmol) in KPi buffer (0.3 M, pH 9, 5 mL) and methanol (2.08 mL), acetophenone (2.92 mL, 25 mmol) was added. The reaction mixture was heated at 70 °C for 20 h and the methanol removed in vacuo. The product was extracted with ethyl acetate (3 × 15 mL) and the organic phases combined, dried, and evaporated. The residue was suspended in dimethyl carbonate (10 mL) and HCl (10 mL, 1 M) and the aqueous phase was washed with dimethyl carbonate (3 × 5 mL) and then evaporated to obtain the crude product. This was dissolved in water–acetonitrile (1:1) and directly purified using the preparative HPLC method III. Fractions were combined, exchanged with HCl (1 M), and evaporated to give 13-HCl (6.0 mg, 4.1%) as a pale yellow solid. The NMR yield of the reaction (11%) was determined following the general procedure described. mp > 200 °C decomposed (H₂O); ν_{\max} (film) 3208, 2961, 2783, 1585 cm⁻¹; ¹H NMR (600 MHz; CD₃OD): δ 7.45–7.39 (m, 3H), 7.35–7.30 (m, 2H), 6.69 (s, 1H), 6.47 (s, 1H), 3.42–3.35 (m, 1H), 3.15–3.05 (m, 2H), 2.98–2.92 (m, 1H), 2.13 (s, 3H); ¹³C{¹H} NMR (151 MHz; CD₃OD): δ 147.2, 146.2, 142.0, 130.4, 130.1, 129.1, 128.0, 123.9, 116.0, 114.6, 63.3, 39.1, 27.3, 25.8; m/z [ES⁺] 256 ([MH]⁺, 100%); m/z [HRMS ES⁺] calcd for C₁₆H₁₈NO₂, 256.1332 [MH]⁺; found, 256.1332.

1-Benzyl-1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol Hydrochloride¹⁹ (14-HCl). To a solution of dopamine hydrochloride (56 mg, 0.30 mmol) and sodium ascorbate (60 mg, 0.30 mmol) in KPi buffer (0.3 M, pH 9, 10 mL) and methanol (10 mL), phenyl acetone (400 μ L, 3.0 mmol) was added. The reaction mixture was heated at 70 °C for 18 h and the methanol removed in vacuo. The product was extracted with ethyl acetate (3 × 20 mL) and the organic phases combined, dried, and evaporated. The residue was resuspended in dimethyl carbonate (10 mL) and HCl (10 mL, 1 M) and the aqueous phase was washed with dimethyl carbonate (4 × 5 mL) and then evaporated to obtain the crude product. This was dissolved in water–acetonitrile (1:1) and was purified (twice) using the preparative HPLC method III. Fractions were combined, exchanged with HCl (1 M), and evaporated to give 14-HCl (2.4 mg, 3%). The NMR yield of the reaction (25%) was determined following the general procedure described. ¹H NMR (700 MHz; CD₃OD): δ 7.36–7.29 (m, 3H), 7.18–7.15 (m, 2H), 6.63 (s, 1H), 6.60 (s, 1H), 3.36–3.32 (m, 3H), 3.25 (d, J = 14.0 Hz, 1H), 2.93 (t, J = 6.3 Hz, 2H), 1.67 (s, 3H); ¹³C{¹H} NMR (176 MHz; CD₃OD): δ 146.6, 145.8, 135.3, 131.8, 129.6, 128.7, 127.9, 122.9, 116.0, 113.5, 60.8, 47.1, 39.0, 26.5, 25.6; m/z [ES⁺] 270 ([MH]⁺, 100%).

1-Ethyl-1-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol Hydrochloride (15-HCl). To a solution of dopamine hydrochloride (19 mg, 0.10 mmol) and sodium ascorbate (20 mg, 0.10 mmol) in KPi buffer (0.3 M, pH 9, 1 mL) and methanol (0.32 mL), 1,1,1-trifluoro-2-butanone (0.68 mL, 5.0 mmol) was added. The reaction mixture was heated at 70 °C for 18 h and monitored by analytical HPLC. The reaction mixture was directly purified using the preparative HPLC method I. Fractions were combined, exchanged with HCl (1 M), and evaporated to give 15-HCl (26 mg, 88%) as a white solid. The NMR yield of the reaction (93%) was determined following the general procedure described. mp 115–117 °C (H₂O); ν_{\max} (film) 3130, 3042, 1526 cm⁻¹; ¹H NMR (600 MHz; CD₃OD): δ 6.81 (s, 1H), 6.70 (s, 1H), 3.60–3.45 (m, 2H), 3.04 (dt, J = 17.4, 6.3 Hz, 1H), 2.96 (dt, J = 17.4, 6.0, 1H), 2.45–2.35 (m, 2H), 1.06 (t, J = 7.8 Hz, 3H); ¹³C{¹H} NMR (151 MHz; CD₃OD): δ 148.4, 146.6, 126.2 (¹ J_{CF} = 285 Hz, CF₃), 126.1, 117.4, 116.7, 113.9, 65.9 (² J_{CF} = 26.7 Hz, CCF₃), 41.6, 28.7, 25.6, 7.8; m/z [ES⁺] 262 ([MH]⁺, 100%); m/z [HRMS ES⁺] calcd for C₁₂H₁₅F₃NO₂, 262.1049 [MH]⁺; found, 262.1049.

3-Methyl-3',4'-dihydro-2'H-spiro[cyclohexane-1,1'-isoquinoline]-6',7'-diol Hydrochloride¹⁹ (16-HCl). Dopamine hydro-

chloride (9.5 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in KPi buffer (0.3 M, pH 9, 500 μ L) and methanol (438.7 μ L) in a capped Eppendorf tube. 3-Methylcyclohexanone (61.3 μ L, 0.50 mmol) was then added and the reaction mixture was shaken under argon at 70 °C. After 20 h the NMR yield (70%) was determined following the general procedure described. Two further duplicate reactions were performed, and the two reaction products were combined and purified using the preparative HPLC method I. Fractions were combined, exchanged with HCl (1 M), and freeze dried to give 16-HCl (8.7 mg, 61%) as a solid. mp > 250 °C (H₂O); ν_{\max} (film) 3196, 2947, 1594, 1394 cm⁻¹; ¹H NMR (600 MHz; CD₃OD): δ 6.73 (s, 1H), 6.57 (s, 1H), 3.42–3.39 (m, 2H), 2.96–2.94 (m, 2H), 2.08–1.99 (m, 2H), 1.93 (td, J = 14.6, 4.4 Hz, 1H), 1.88–1.81 (m, 2H), 1.78–1.69 (m, 1H), 1.68–1.60 (m, 2H), 1.13 (dq, J = 12.6, 4.2 Hz, 1H), 1.00 (d, J = 6.3 Hz, 3H); ¹³C{¹H} NMR (151 MHz; CD₃OD): δ 146.5, 146.1, 129.6, 123.0, 116.1, 113.2, 61.7, 45.3, 38.7, 36.3, 34.1, 28.3, 26.2, 22.5, 21.6; m/z [HRMS ES⁺] calcd for C₁₅H₂₂NO₂, 248.1651 [MH]⁺; found, 248.1664.

4-Methyl-3',4'-dihydro-2'H-spiro[cyclohexane-1,1'-isoquinoline]-6',7'-diol Hydrochloride¹⁹ (17-HCl). Dopamine hydrochloride (9.5 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in KPi buffer (0.3 M, pH 9, 500 μ L) and methanol (438.7 μ L) in a capped Eppendorf tube. 4-Methylcyclohexanone (61.3 μ L, 0.50 mmol) was then added and the reaction mixture was shaken under argon at 70 °C. After 20 h the NMR yield (80%) was determined following the general procedure described. Two further duplicate reactions were performed, and the two reaction products were combined and purified using the preparative HPLC method I. Fractions were combined, exchanged with HCl (1 M), and freeze dried to give 17-HCl (9.5 mg, 67%) as a solid. mp > 250 °C (H₂O); ν_{\max} (film) 3196, 2947, 1594, 1394 cm⁻¹; ¹H NMR (600 MHz; CD₃OD): δ 6.73 (s, 1H), 6.57 (s, 1H), 3.41 (t, J = 6.4 Hz, 2H), 2.95 (t, J = 6.4 Hz, 2H), 2.10–2.05 (m, 4H), 1.78 (dd, J = 15.0, 1.8 Hz, 2H), 1.69–1.60 (m, 1H), 1.36–1.22 (m, 2H), 1.03 (d, J = 6.5 Hz, 3H); ¹³C{¹H} NMR (151 MHz; CD₃OD): δ 146.5, 146.1, 129.5, 123.2, 116.1, 113.2, 60.6, 38.7, 36.9, 32.4, 30.1, 26.2, 22.2; m/z [HRMS ES⁺] calcd for C₁₅H₂₂NO₂, 248.1651 [MH]⁺; found, 248.1661.

4-Isopropyl-3',4'-dihydro-2'H-spiro[cyclohexane-1,1'-isoquinoline]-6',7'-diol Hydrochloride (18-HCl). Dopamine hydrochloride (9.5 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in KPi buffer (0.3 M, pH 9, 500 μ L) and methanol (463 μ L) in a capped Eppendorf tube. 4-Isopropylcyclohexanone (70 mg, 0.50 mmol) was then added and the reaction mixture was shaken under argon at 70 °C. After 20 h the NMR yield (75%) was determined following the general procedure described. Two further duplicate reactions were performed, and the two reaction products were combined and purified using the preparative HPLC method III. Fractions were combined, exchanged with HCl (1 M), and freeze dried to give 18-HCl (8.3 mg, 53%) as a white solid. mp > 250 °C (H₂O); ν_{\max} (film) 3223, 2931, 1652, 1524 cm⁻¹; ¹H NMR (600 MHz; CD₃OD): δ 6.73 (s, 1H), 6.57 (s, 1H), 3.41 (t, J = 6.4 Hz, 2H), 2.95 (t, J = 6.4 Hz, 2H), 2.08 (m, 4H), 1.91–1.84 (m, 2H), 1.57–1.48 (m, 1H), 1.34–1.25 (m, 3H), 0.97 (d, J = 6.8 Hz, 6H); ¹³C NMR (151 MHz; CD₃OD): δ 146.5, 146.1, 129.5, 123.2, 116.1, 113.2, 60.9, 44.1, 38.8, 37.2, 33.9, 26.3, 25.5, 20.3; m/z [ES⁺] 276 ([MH]⁺, 100%); m/z [HRMS ES⁺] calcd for C₁₇H₂₆NO₂, 276.1958 [MH]⁺; found, 276.1960.

2',3',3',4',5',6'-Hexahydro-2H-spiro[isoquinoline-1,4'-pyran]-6,7-diol Hydrochloride (19-HCl). Dopamine hydrochloride (9.5 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in KPi buffer (0.3 M, pH 9, 500 μ L) and methanol (453.8 μ L) in a capped Eppendorf tube. Tetrahydro-4H-pyran-4-one (46.2 μ L, 0.50 mmol) was then added and the reaction mixture was shaken under argon at 70 °C. After 20 h the NMR yield (83%) was determined following the general procedure described. Two further duplicate reactions were performed, and the two reaction products were combined and purified using the preparative HPLC method III. Fractions were combined, exchanged with HCl (1 M), and freeze dried to give 19-HCl (8.9 mg, 65%) as a white solid. mp 200 °C

decomposed (H₂O); ν_{\max} (film) 3223, 2969, 1591, 1525 cm⁻¹; ¹H NMR (600 MHz; CD₃OD): δ 6.79 (s, 1H), 6.59 (s, 1H), 3.97 (dd, J = 12.6, 4.5 Hz, 2H), 3.76 (td, J = 12.6, 2.0 Hz, 2H), 3.48 (t, J = 6.4 Hz, 2H), 2.98 (t, J = 6.4 Hz, 2H), 2.35 (ddd, J = 15.4, 12.6, 4.5 Hz, 2H), 2.00 (m, 2H); ¹³C{¹H} NMR (151 MHz; CD₃OD): δ 146.9, 146.3, 128.5, 123.4, 116.2, 113.4, 63.3, 58.7, 39.0, 36.8, 26.1; m/z [ES⁺] 236 ([MH]⁺, 100%); m/z [HRMS ES⁺] calcd for C₁₃H₁₈NO₃, 236.1281 [MH]⁺; found, 236.1282.

3',4'-Dihydro-2'H-spiro[cyclobutane-1,1'-isoquinoline]-6',7'-diol Hydrochloride (20·HCl). Dopamine hydrochloride (9.5 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in KPi buffer (0.3 M, pH 9, 500 μ L) and methanol (463 μ L) in a capped Eppendorf tube. Cyclobutanone (37 μ L, 0.50 mmol) was then added and the reaction mixture was shaken under argon at 70 °C. After 20 h the NMR yield (97%) was determined following the general procedure described. Two further duplicate reactions were performed, and the two reaction products were combined and purified using the preparative HPLC method III. Fractions were combined, exchanged with HCl (1 M), and freeze dried to give 20·HCl (8.9 mg, 74%) as a white solid. The reaction was scaled-up using 5·HCl (1.00 g, 5.27 mmol) sodium ascorbate (1 equiv with respect to dopamine) in KPi buffer (0.3 M, pH 9, 52.7 mL) and methanol (52.7 mL), and cyclobutanone was added (3.92 mL, 52.7 mmol). The reaction mixture was shaken at 70 °C for 20 h, and then the pH was adjusted to 3 by the addition of HCl (2 M). The solvent was removed in vacuo, and the residue suspended in acetonitrile at 0 °C. Finally, the mixture was filtered and the solvent removed in vacuo to give 20·HCl (0.646 g, 51%). mp > 250 °C (H₂O); ν_{\max} (film) 3155, 2947, 1578, 1398 cm⁻¹; ¹H NMR (600 MHz; CD₃OD): δ 7.03 (s, 1H), 6.57 (s, 1H), 3.36 (t, J = 6.4 Hz, 2H), 2.93 (t, J = 6.4 Hz, 2H), 2.59 (t, J = 8.3 Hz, 4H), 2.22 (m, 2H); ¹³C{¹H} NMR (151 MHz; CD₃OD): δ 146.9, 146.4, 128.5, 122.8, 115.8, 112.4, 61.3, 39.5, 35.1, 26.1, 14.2; m/z [ES⁺] 206 ([MH]⁺, 100%); m/z [HRMS ES⁺] calcd for C₁₂H₁₆NO₂, 206.1176 [MH]⁺; found, 206.1176.

3',4'-Dihydro-2'H-spiro[cyclopentane-1,1'-isoquinoline]-6',7'-diol Hydrochloride (21·HCl). Dopamine hydrochloride (9.5 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in KPi buffer (0.3 M, pH 9, 500 μ L) and methanol (456 μ L) in a capped Eppendorf tube. Cyclopentanone (44 μ L, 0.50 mmol) was then added and the reaction mixture shaken under argon at 70 °C. After 20 h the NMR yield (95%) was determined following the general procedure described. Two further duplicate reactions were performed, and the two reaction products were combined and purified using the preparative HPLC method III. Fractions were combined, exchanged with HCl (1 M), and freeze dried to give 21·HCl (9.8 mg, 77%) as a solid. mp > 200 °C decomposed (H₂O); ν_{\max} (film) 3223, 2970, 1592 cm⁻¹; ¹H NMR (600 MHz; CD₃OD): δ 6.66 (s, 1H), 6.55 (s, 1H), 3.42 (t, J = 6.4 Hz, 2H), 2.95 (t, J = 6.4 Hz, 2H), 2.24–2.12 (m, 4H), 2.0–1.98 (m, 2H), 1.98–1.90 (m, 2H); ¹³C{¹H} NMR (151 MHz; CD₃OD): δ 146.5, 146.3, 129.6, 123.1, 115.8, 112.8, 68.8, 42.0, 40.3, 26.0, 25.9; m/z [ES⁺] 220 ([MH]⁺, 100%); m/z [HRMS ES⁺] calcd for C₁₃H₁₈NO₂, 220.1332 [MH]⁺; found, 220.1329.

1,3,3',4'-Tetrahydro-2'H-spiro[indene-2,1'-isoquinoline]-6',7'-diol Hydrochloride (22·HCl). Dopamine hydrochloride (56 mg, 0.30 mmol), sodium ascorbate (60 mg, 0.30 mmol), and 2-indanone (396 mg, 3.0 mmol) were mixed in KPi buffer (0.3 M, pH 9, 10 mL) and methanol (10 mL). The reaction mixture was stirred at 70 °C for 18 h, and then diluted to 50 mL with water. The brown insoluble precipitate was removed by filtration and the filtrate extracted with ethyl acetate (4 \times 20 mL). The organic phase was washed with brine (2 \times 20 mL), dried, filtered, and evaporated to obtain the crude product. The residue was washed with cold ethanol, stirred in HCl (1 M) for 4 h and the solvent removed in vacuo (<55 °C) to give 22·HCl (38 mg, 57%) as a white solid. The NMR yield (70%) was determined following the general procedure described. mp > 240 °C decomposed (H₂O); ν_{\max} (film) 3396 (br), 1621, 1590, 1524 cm⁻¹; ¹H NMR (600 MHz; CD₃OD): δ 7.35–7.27 (m, 4H), 6.60 (s, 1H), 6.56 (s, 1H), 3.60 (d, J = 17.1 Hz, 2H), 3.56 (d, J = 17.1 Hz, 2H), 3.51 (t, J = 6.6 Hz, 2H), 3.03 (t, J = 6.6 Hz, 2H); ¹³C{¹H}

NMR (151 MHz; CD₃OD): δ 147.0, 146.3, 140.0, 129.1, 128.9, 125.9, 122.9, 116.0, 112.1, 67.8, 48.1, 40.5, 26.0; m/z [ES⁺] 268 ([MH]⁺, 100%); m/z [HRMS ES⁺] calcd for C₁₇H₁₈NO₂, 268.1332 [MH]⁺; found, 268.1332.

2,3,3',4'-Tetrahydro-2'H-spiro[indene-1,1'-isoquinoline]-6',7'-diol Hydrochloride (23·HCl). Dopamine hydrochloride (9.5 mg, 0.050 mmol), sodium ascorbate (10 mg, 0.050 mmol) and 1-indanone (66 mg, 0.5 mmol) were mixed in KPi buffer (0.3 M, pH 9, 500 μ L) and methanol (500 μ L) in a capped Eppendorf tube. The reaction mixture was shaken under argon at 70 °C. After 20 h the NMR yield (21%) was determined following the general procedure described. Two further duplicate reactions were performed, and the two reaction products were combined and purified using the preparative HPLC method I. Fractions were combined, exchanged with HCl (1 M), and solvent removed in vacuo (<55 °C) to give 23·HCl (2.1 mg, 7%) as a white solid. mp > 240 °C decomposed (H₂O); ν_{\max} (film) 3142, 2946, 2791, 1605, 1408 cm⁻¹; ¹H NMR (700 MHz; CD₃OD): δ 7.48–7.42 (m, 2H), 7.32 (t, J = 7.0 Hz, 1H), 7.14 (d, J = 7.0 Hz, 1H), 6.66 (s, 1H), 6.16 (s, 1H), 3.60–3.48 (m, 2H), 3.30–3.24 (m, 1H), 3.23–3.14 (m, 2H), 3.02 (dt, J = 16.8, 4.2 Hz, 1H), 2.81–2.72 (m, 1H), 2.60 (dt, J = 16.8, 8.4 Hz, 1H); ¹³C NMR (176 MHz; CD₃OD): δ 146.9, 146.0, 145.9, 143.5, 131.3, 128.6, 127.6, 126.40, 126.36, 123.8, 115.5, 114.2, 71.8, 41.0, 40.0, 30.1, 25.6; m/z [ES⁺] 268 ([MH]⁺, 100%); m/z [HRMS ES⁺] calcd for C₁₇H₁₈NO₂, 268.1332 [MH]⁺; found, 268.1331.

3',4'-Dihydro-2'H-spiro[cyclohexane-1,1'-isoquinolin]-6'-ol Hydrochloride (24·HCl). 2-(3-Hydroxyphenyl)ethylamine hydrochloride²⁰ (8.7 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in KPi buffer (0.3 M, pH 9, 500 μ L) and methanol (241 μ L) in a capped Eppendorf tube. Cyclohexanone (259 μ L, 2.5 mmol) was added and the mixture was shaken under argon at 70 °C. After 20 h the NMR yield (74%) was determined following the general procedure described. Two further duplicate reactions were performed, and the two reaction products were combined and then purified using the preparative HPLC method I. Fractions were combined, exchanged with HCl (1 M), and the solvent removed in vacuo (<55 °C) to give 24·HCl (7.1 mg, 55%) as a solid. mp > 250 °C (H₂O); ν_{\max} (film) 3217, 2930, 2766, 1589, 1440 cm⁻¹; ¹H NMR (700 MHz; CD₃OD): δ 7.24 (d, J = 7.8 Hz, 1H), 6.74 (dd, J = 7.8, 2.1 Hz, 1H), 6.60 (d, J = 2.1 Hz, 1H), 3.45 (t, J = 6.3 Hz, 2H), 3.06 (t, J = 6.3 Hz, 2H), 2.09–2.03 (m, 4H), 1.87–1.79 (m, 3H), 1.70–1.62 (m, 2H), 1.55–1.45 (m, 1H); ¹³C{¹H} NMR (176 MHz; CD₃OD): δ 157.8, 133.1, 129.5, 128.1, 115.9, 115.7, 61.0, 38.2, 36.6, 26.7, 25.0, 21.5; m/z [ES⁺] 218 ([MH]⁺, 100%); m/z [HRMS ES⁺] calcd for C₁₄H₂₀NO, 218.1539 [MH]⁺; found, 218.1539.

7'-Fluoro-3',4'-dihydro-2'H-spiro[cyclohexane-1,1'-isoquinolin]-6'-ol Hydrochloride (25·HCl). To a solution of 2-(4-fluoro-3-hydroxyphenyl)ethylamine hydrobromide²⁰ (23.6 mg, 0.10 mmol) and sodium ascorbate (20 mg, 0.10 mmol) in KPi buffer (0.3 M, pH 9, 1 mL) and methanol (0.32 mL), cyclohexanone (518 μ L, 5.0 mmol) was added. The reaction mixture was heated at 70 °C for 20 h and the methanol was removed in vacuo. The solution was freeze-dried, dissolved in water–acetonitrile (1:1), and centrifuged at 4000 rpm for 10 min. The supernatant was then purified by the preparative HPLC method I. Fractions were combined, exchanged with HCl (1 M), and evaporated (at <55 °C) to give 25·HCl (14 mg, 50%) as a white solid. The NMR yield of the reaction (55%) was determined following the general procedure described. mp > 250 °C (H₂O); ν_{\max} (film) 3150, 3061, 2942, 2762, 1525 cm⁻¹; ¹H NMR (600 MHz; CD₃OD): δ 7.18 (d, ³J_{HF} = 12.6 Hz, 1H), 6.74 (d, ⁴J_{HF} = 8.4 Hz, 1H), 3.45 (t, J = 6.2 Hz, 2H), 3.03 (t, J = 6.2 Hz, 2H), 2.11–1.97 (m, 4H), 1.89–1.74 (m, 3H), 1.73–1.59 (m, 2H), 1.56–1.42 (m, 1H); ¹³C{¹H} NMR (151 MHz; CD₃OD): δ 152.1 (d, ¹J_{CF} = 241 Hz), 145.9 (d, ²J_{CF} = 13.4 Hz), 130.3, 128.4, 118.6 (d, J_{CF} = 3.0 Hz), 114.4 (d, J_{CF} = 21.0 Hz), 61.0, 38.4, 36.6, 26.3, 25.1, 21.6; m/z [ES⁺] 236 ([MH]⁺, 100%); m/z [HRMS ES⁺] calcd for C₁₄H₁₉FNO, 236.1445 [MH]⁺; found, 236.1446.

5-(2-Aminoethyl)benzene-1,3-diol Hydrobromide.³⁶ The reaction was carried out under anhydrous conditions. To a solution of 3,5-dimethoxyphenyl acetonitrile (753 mg, 4.25 mmol) in THF (10

mL), borane–THF solution (1 M; 13 mL, 13 mmol) was added at 0 °C. The reaction was stirred for 24 h at room temperature, cooled to 0 °C, and methanol (30 mL) was added. The solution was then stirred for another 24 h, concentrated under vacuum, and coevaporated with methanol (3 × 10 mL). The residue was purified by silica column chromatography (dichloromethane–methanol (containing 1% triethylamine), 9:1 to 5:1) to give 2-(3,5-dimethoxyphenyl)ethan-1-amine³⁷ (427 mg, 55%) as an oil. R_f = 0.13 [dichloromethane–methanol (containing 1% triethylamine), 9:1]; $^1\text{H NMR}$ (600 MHz; CDCl_3): δ 6.36–6.34 (m, 2H), 6.32 (t, J = 2.4 Hz, 1H), 3.77 (s, 6H), 2.96 (t, J = 7.2 Hz, 2H), 2.70 (t, J = 7.2 Hz, 2H), 2.12 (br s, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz; CDCl_3): δ 161.0, 142.1, 107.0, 98.2, 55.4, 43.2, 40.0.

2-(3,5-Dimethoxyphenyl)ethan-1-amine (427 mg, 2.36 mmol) was stirred in dichloromethane (20 mL) and boron tribromide (1 M; 7.5 mL, 7.5 mmol) at room temperature for 24 h. Methanol (30 mL) was then added and the reaction stirred for another 3 h. The mixture was then concentrated under vacuum and coevaporated with methanol to give 5-(2-aminoethyl)benzene-1,3-diol-HBr³⁶ (572 mg, 100%) as the HBr salt. $^1\text{H NMR}$ (600 MHz; CD_3OD): δ 6.23 (d, J = 2.3 Hz, 2H), 6.19 (t, J = 2.3 Hz, 1H), 3.14 (t, J = 7.8 Hz, 2H), 2.82 (t, J = 7.8 Hz, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz; CD_3OD): δ 160.0, 140.0, 108.2, 102.5, 41.9, 34.5; m/z [ES^+] 154 ($[\text{MH}]^+$, 100%).

3',4'-Dihydro-2'H-spiro[cyclohexane-1,1'-isoquinoline]-6',8'-diol Hydrochloride (26·HCl). 3,5-Dihydroxyl phenethylamine hydrobromide (11.7 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in KPi buffer (0.3 M, pH 9, 500 μL) and methanol (241 μL) in a capped Eppendorf tube. Cyclohexanone (259 μL , 2.5 mmol) was added and the mixture shaken under argon at 70 °C. After 20 h the NMR yield (57%) was determined following the general procedure described. Two further duplicate reactions were performed, and the two reaction products were combined and then purified using the preparative HPLC method I. Fractions were combined, exchanged with HCl (1 M), and the solvent removed in vacuo (<55 °C) to give 26·HCl (5.0 mg, 37%) as a solid. mp > 250 °C (H_2O); ν_{max} (film) 3232, 3092, 2861, 1590 cm^{-1} ; $^1\text{H NMR}$ (600 MHz; CD_3OD): δ 6.23 (d, J = 2.4 Hz, 1H), 6.14 (d, J = 2.4 Hz, 1H), 3.34 (t, J = 6.0 Hz, 2H), 3.04–2.95 (m, 4H), 1.82–1.73 (m, 5H), 1.67–1.53 (m, 2H), 1.50–1.34 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz; CD_3OD): δ 158.7, 157.1, 134.9, 116.1, 108.1, 103.8, 61.6, 38.3, 31.8, 28.0, 25.1, 21.6; m/z [ES^+] 256 ($[\text{MNa}]^+$, 29%), 234 ($[\text{MH}]^+$, 75); m/z [HRMS ES^+] calcd for $\text{C}_{14}\text{H}_{20}\text{NO}_2$, 234.1489 [$\text{MH}]^+$; found, 234.1489.

8,9-Dihydroxy-10b-methyl-1,5,6,10b-tetrahydropyrrolo-[2,1-a]isoquinolin-3(2H)-one (29). Dopamine hydrochloride (9.5 mg, 0.050 mmol) and sodium ascorbate (10.5 mg, 0.053 mmol) were mixed in KPi buffer (0.3 M, pH 9, 500 μL) and methanol (200 μL) in a capped Eppendorf tube. Methyl levulinate 28 (300 μL , 2.5 mmol) was added and the mixture shaken under argon at 70 °C for 20 h. A duplicate reaction was performed, these two reactions were combined and methanol removed in vacuo. The solution was freeze-dried and the NMR yield of the reaction (50%) determined following the general procedure described. The product was then purified using the preparative HPLC method I. Fractions were combined, exchanged with HCl (1 M), and the solvent removed in vacuo (<55 °C) to give 29·HCl (4.4 mg, 19%) as a white solid. mp > 237–238 °C (H_2O); ν_{max} (film) 3246 (br), 2966, 1644, 1520 cm^{-1} ; $^1\text{H NMR}$ (700 MHz; CD_3OD): δ 6.57 (s, 1H), 6.50 (s, 1H), 4.12 (dd, J = 13.3, 6.3 Hz, 1H), 3.11 (td, J = 13.3, 4.7 Hz, 1H), 2.75–2.69 (m, 1H), 2.67–2.60 (m, 2H), 2.41–2.33 (m, 2H), 2.06–2.00 (m, 1H), 1.49 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz; CD_3OD): δ 174.8, 145.4, 145.2, 134.9, 124.1, 116.0, 112.4, 62.8, 35.7, 35.4, 31.4, 28.6, 27.2; m/z [ES^+] 234 ($[\text{MH}]^+$, 100%); m/z [HRMS ES^+] calcd for $\text{C}_{13}\text{H}_{16}\text{NO}_3$, 234.1125 [$\text{MH}]^+$; found, 234.1126.

■ ASSOCIATED CONTENT

● Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.9b00527.

Supplementary figures and tables and $^1\text{H NMR}$ and $^{13}\text{C NMR}$ spectra of all new products (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: h.c.hailes@ucl.ac.uk.

ORCID

Helen C. Hailes: 0000-0001-5574-4742

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We gratefully acknowledge UCL Dean's Prize and UCL-China Scholarship Council Joint Research Scholarship for funding J.Z. and the Biotechnology and Biosciences Research Council (BBRSC) (BB/N01877X/1) for funding D.M.-S. We acknowledge equipment support from the Engineering and Physical Sciences Research Council (EPSRC) (EP/P020410/1). We also thank K. Karu (UCL Mass Spectrometry Facility) and A. E. Aliev (UCL NMR Facility) in the Department of Chemistry.

■ REFERENCES

- (1) Dastmalchi, M.; Park, M. R.; Morris, J. S.; Facchini, P. Family portraits: the enzymes behind benzyloisoquinoline alkaloid diversity. *Phytochem. Rev.* **2018**, *17*, 249–277.
- (2) Stermitz, F. R.; Lorenz, P.; Tawara, J. N.; Zenewicz, L. A.; Lewis, K. Synergy in a medicinal plant: Antimicrobial action of berberine potentiated by 5-methoxyhydrnocarpin, a multidrug pump inhibitor. *Proc. Natl. Acad. Sci. U. S. A.* **2000**, *97*, 1433–1437.
- (3) Zou, Z.-h.; Lan, X.-b.; Qian, H.; Huang, W.-l.; Li, Y.-m. Synthesis and evaluation of furoxan-based nitric oxide-releasing derivatives of tetrahydroisoquinoline as anticancer and multidrug resistance reversal agents. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 5934–5938.
- (4) Scott, J. D.; Williams, R. M. Chemistry and Biology of the Tetrahydroisoquinoline Antitumor Antibiotics. *Chem. Rev.* **2002**, *102*, 1669–1730.
- (5) Cortijo, J.; Villagrana, V.; Pons, R.; Berto, L.; Marti-Cabrera, M.; Martinez-Losa, M.; Domenech, T.; Beleta, J.; Morcillo, E. J. Bronchodilator and anti-inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes. *Br. J. Pharmacol.* **1999**, *127*, 1641–1651.
- (6) Kashiwada, Y.; Aoshima, A.; Ikeshiro, Y.; Chen, Y.-P.; Furukawa, H.; Itoigawa, M.; Fujioka, T.; Mihashi, K.; Cosentino, L. M.; Morris-Natschke, S. L.; Lee, K.-H. Anti-HIV benzyloisoquinoline alkaloids and flavonoids from the leaves of *Nelumbo nucifera*, and structure–activity correlations with related alkaloids. *Bioorg. Med. Chem.* **2005**, *13*, 443–448.
- (7) Scott, J. S.; Bailey, A.; Davies, R. D. M.; Degorce, S. L.; MacFaul, P. A.; Gingell, H.; Moss, T.; Norman, R. A.; Pink, J. H.; Rabow, A. A.; Roberts, B.; Smith, P. D. Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat. *ACS Med. Chem. Lett.* **2016**, *7*, 94–99.
- (8) Singh, I. P.; Shah, P. Tetrahydroisoquinolines in therapeutics: a patent review (2010–2015). *Expert Opin. Ther. Pat.* **2017**, *27*, 17–36.
- (9) Irie, H.; Kishimoto, T.; Uyeo, S. The total synthesis of (\pm)-ochotensine and related compounds. *J. Chem. Soc. C* **1968**, 3051–3057.
- (10) Hanna, J. N.; Ntie-Kang, F.; Kaiser, M.; Brun, R.; Efang, S. M. N. 1-Aryl-1,2,3,4-tetrahydroisoquinolines as potential antimalarials: synthesis, in vitro antiparasitic activity and in silico pharmacokinetics evaluation. *RSC Adv.* **2014**, *4*, 22856–22865.
- (11) Toyoshima, R.; Mori, N.; Suzuki, T.; Lowtangkitcharoen, W.; Suwanborirux, K.; Saito, N. Chemistry of Ecteinascidins. Part 5: An Additional Proof of Cytotoxicity Evaluation of Ecteinascidin 770 Derivatives. *Chem. Pharm. Bull.* **2016**, *64*, 966–969.

- (12) Bonamore, A.; Rovardi, I.; Gasparrini, F.; Baiocco, P.; Barba, M.; Molinaro, C.; Botta, B.; Boffi, A.; Macone, A. An enzymatic, stereoselective synthesis of (S)-norcoclaurine. *Green Chem.* **2010**, *12*, 1623–1627.
- (13) Ilari, A.; Franceschini, S.; Bonamore, A.; Arengi, F.; Botta, B.; Macone, A.; Pasquo, A.; Bellucci, L.; Boffi, A. Structural Basis of Enzymatic (S)-Norcoclaurine Biosynthesis. *J. Biol. Chem.* **2009**, *284*, 897–904.
- (14) Lichman, B. R.; Gershater, M. C.; Lamming, E. D.; Pesnot, T.; Sula, A.; Keep, N. H.; Hailes, H. C.; Ward, J. M. Dopamine-first mechanism enables the rational engineering of the norcoclaurine synthase aldehyde activity profile. *FEBS J.* **2015**, *282*, 1137–1151.
- (15) Lichman, B. R.; Sula, A.; Pesnot, T.; Hailes, H. C.; Ward, J. M.; Keep, N. H. Structural Evidence for the Dopamine-First Mechanism of Norcoclaurine Synthase. *Biochemistry* **2017**, *56*, 5274–5277.
- (16) Pesnot, T.; Gershater, M. C.; Ward, J. M.; Hailes, H. C. The Catalytic Potential of *Coptis japonica* NCS2 Revealed - Development and Utilisation of a Fluorescamine-Based Assay. *Adv. Synth. Catal.* **2012**, *354*, 2997–3008.
- (17) Ruff, B. M.; Bräse, S.; O'Connor, S. E. Biocatalytic production of tetrahydroisoquinolines. *Tetrahedron Lett.* **2012**, *53*, 1071–1074.
- (18) Nishihachijo, M.; Hirai, Y.; Kawano, S.; Nishiyama, A.; Minami, H.; Katayama, T.; Yasohara, Y.; Sato, F.; Kumagai, H. Asymmetric synthesis of tetrahydroisoquinolines by enzymatic Pictet-Spengler reaction. *Biosci., Biotechnol., Biochem.* **2014**, *78*, 701–707.
- (19) Lichman, B. R.; Zhao, J.; Hailes, H. C.; Ward, J. M. Enzyme catalysed Pictet-Spengler formation of chiral 1,1'-disubstituted- and spiro-tetrahydroisoquinolines. *Nat. Commun.* **2017**, *8*, 14883.
- (20) Zhao, J.; Lichman, B. R.; Ward, J. M.; Hailes, H. C. One-pot chemoenzymatic synthesis of trolline and tetrahydroisoquinoline analogues. *Chem. Commun.* **2018**, *54*, 1323–1326.
- (21) Pictet, A.; Spengler, T. Über die Bildung von Isochinolin-derivaten durch Einwirkung von Methylal auf Phenyl-äthylamin, Phenyl-alanin und Tyrosin. *Ber. Dtsch. Chem. Ges.* **1911**, *44*, 2030–2036.
- (22) Bischler, A.; Napieralski, B. Zur Kenntniss einer neuen Isochinolinsynthese. *Ber. Dtsch. Chem. Ges.* **1893**, *26*, 1903–1908.
- (23) Youn, S. W. The Pictet-Spengler Reaction: Efficient Carbon-Carbon Bond Forming Reaction in Heterocyclic Synthesis. *Org. Prep. Proced. Int.* **2006**, *38*, 505–591.
- (24) Yokoyama, A.; Ohwada, T.; Shudo, K. Prototype Pictet-Spengler Reactions Catalyzed by Superacids. Involvement of Dicationic Superlectrophiles. *J. Org. Chem.* **1999**, *64*, 611–617.
- (25) Kametani, T.; Kigasawa, K.; Hiiragi, M.; Ishimaru, H. Phenolic cyclization. IV. The mechanism of isoquinoline formation (studies on the syntheses of heterocyclic compounds. CCCXXXVII). *Chem. Pharm. Bull.* **1969**, *17*, 2353–2357.
- (26) Kametani, T.; Fukumoto, K.; Kigasawa, K.; Hiiragi, M.; Ishimaru, H. Synthesis of the 1,2,3,4-tetrahydroisoquinolines and related compounds by phenolic cyclization. *Heterocycles* **1975**, *3*, 311–341.
- (27) Barbero, M.; Bazzi, S.; Cadamuro, S.; Dughera, S. *o*-Benzenedisulfonimide as a reusable acid catalyst for an easy, efficient, and green synthesis of tetrahydroisoquinolines and tetrahydro- β -carboline through Pictet-Spengler reaction. *Tetrahedron Lett.* **2010**, *51*, 6356–6359.
- (28) Horiguchi, Y.; Kodama, H.; Nakamura, M.; Yoshimura, T.; Hanezi, K.; Hamada, H.; Saitoh, T.; Sano, T. A Convenient Synthesis of 1,1-Disubstituted 1,2,3,4-Tetrahydroisoquinolines via Pictet-Spengler Reaction Using Titanium(IV) Isopropoxide and Acetic-Formic Anhydride. *Chem. Pharm. Bull.* **2002**, *50*, 253–257.
- (29) Vanden Eynden, M. J.; Kunchithapatham, K.; Stambuli, J. P. Calcium-Promoted Pictet-Spengler Reactions of Ketones and Aldehydes. *J. Org. Chem.* **2010**, *75*, 8542–8549.
- (30) Pesnot, T.; Gershater, M. C.; Ward, J. M.; Hailes, H. C. Phosphate mediated biomimetic synthesis of tetrahydroisoquinoline alkaloids. *Chem. Commun.* **2011**, *47*, 3242–3244.
- (31) Morita, S.; Ito, T.; Tono, T. Syntheses of Isoquinolines by Condensation of Dopamine with Carbonyl Compounds. *Agric. Biol. Chem.* **1975**, *39*, 547–549.
- (32) Tono, T. A tetrahydroisoquinoline derivative isolated from the acetone extract of *Dioscorea batatas*. *Agric. Biol. Chem.* **1971**, *35*, 619–621.
- (33) Francisco, M. C.; Nasser, A. L. M.; Lopes, L. M. X. Tetrahydroisoquinoline alkaloids and 2-deoxyribonolactones from *Aristolochia arcuata*. *Phytochemistry* **2003**, *62*, 1265–1270.
- (34) Parra, R. D.; Maresh, J. Structural and energetics aspects of a proposed mechanism for the phosphate-mediated Pictet-Spengler cyclization reaction: A computational study. *Comput. Theor. Chem.* **2016**, *1082*, 1–10.
- (35) Maresh, J. J.; Crowe, S. O.; Ralko, A. A.; Aparece, M. D.; Murphy, C. M.; Krzeszowiec, M.; Mullaney, M. W. Facile one-pot synthesis of tetrahydroisoquinolines from amino acids via hypochlorite-mediated decarboxylation and Pictet-Spengler condensation. *Tetrahedron Lett.* **2014**, *55*, 5047–5051.
- (36) Bailey, A. S.; Bates, D. H.; Ing, H. R.; Warne, M. A. 2-(3,5-Dihydroxyphenyl)ethylamine and 3,5-dihydroxyphenylalanine. *J. Chem. Soc.* **1952**, 4534–4535.
- (37) Qian, W.; Lu, W.; Sun, H.; Li, Z.; Zhu, L.; Zhao, R.; Zhang, L.; Zhou, S.; Zhou, Y.; Jiang, H.; Zhen, X.; Liu, H. Design, synthesis and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor. *Bioorg. Med. Chem.* **2012**, *20*, 4862–4871.